Search the Newsreel

Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC

Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 30% in the second quarter, selling 358,669 shares and retaining 835,204 shares valued at $3.06 million. The company's shares opened at $3.71, near its 12-month low, and it reported a quarterly loss …

Fulcrum Therapeutics stock plunges 51% after FD...

Fulcrum Therapeutics' stock plummeted 51% after the FDA halted development of its sickle cell disease drug, pociredir, due to serious safety concerns. The FDA's decision, prompted by malignancy risks linked to similar drugs, effectively ends clinical development for pociredir, significantly impacting Fulcrum's future. This …

Fulcrum Metals reports change in significant shareholding as it advances cyanide-free tailings projects

REG - Fulcrum Metals PLC - Holding(s) in Company

Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com

This article announces that Fulcrum Therapeutics Inc. filed a Form 8K on August 10th. The filing is a standard corporate disclosure that typically reports significant events relevant to shareholders. The brief piece is published by Investing.com, a financial markets news outlet.

Fulcrum Therapeutics appoints Alan Musso as principal accounting officer

Fulcrum Therapeutics announced that Alan Musso, its current chief financial officer, has been appointed to the additional role of principal accounting officer, effective August 7, 2026. This appointment follows the departure of Greg Tourangeau from the Vice President, Finance and principal accounting officer position. …

Fulcrum Metals Secures Additional Terra North Equity in Amended Saskatchewan Uranium Deal

Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Fulcrum Metals increases Terra North equity exposure under revised uranium agreement

Fulcrum Metals (FMET) Updates Saskatchewan Uranium Option Deal, Receives C$560,000 via Terra North Shares

REG - Fulcrum Metals PLC - Amendment to Saskatchewan uranium option agreement

BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $3

BofA Securities has maintained its Sell rating on Fulcrum Therapeutics (FULC.US) and kept its target price at $3. This indicates a continued bearish outlook from the firm regarding the company's stock performance.

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program for sickle cell disease. The discontinuation followed heightened FDA concerns about the drug's benefit-risk profile due to malignancy risks associated with …

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts

Fulcrum Therapeutics (NASDAQ:FULC) has received a consensus "Reduce" recommendation from analysts, with an average 12-month price target of $8.20. Several firms recently downgraded the stock and set lower price targets. This comes as the company missed quarterly earnings expectations and its shares remain significantly …

Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits …

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about malignancy risk. This news led to a significant 51.09% drop in Fulcrum …

Fulcrum Lithium Unveils Major Alkali Flats Resource in Nevada

Fulcrum Therapeutics, Inc. 2Q 2026: Net loss $(26.2M), EPS $(0.34) — 10-Q Summary

Fulcrum Therapeutics, Inc. reported a significant net loss of $(26.2M) and diluted EPS of $(0.34) for 2Q 2026, widening from the previous year, with no revenue generated. The company discontinued its sickle cell disease program, reduced its workforce by 85%, and initiated a strategic …

Truist Financial Downgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Cuts Target Price to $4

Truist Financial has downgraded Fulcrum Therapeutics (FULC.US) to a Hold rating from a Buy rating, citing increased risk in their FA/FSHD programs. The firm has also significantly cut its price target for FULC.US from $15 to $4. This adjustment reflects a more cautious outlook …

Fulcrum Therapeutics (NASDAQ:FULC) Posts Earnings Results, Misses Expectations By $0.13 EPS

Fulcrum Therapeutics Market Sentiment

This article analyzes the market sentiment for Fulcrum Therapeutics (FULC) based on several key signals: analyst consensus, short interest, options flow, and insider activity. The overall analyst consensus is "Hold" with a target price of $8.00, while short interest is rising, and insider activity …

Fulcrum Therapeutics (NASDAQ: FULC) ends pociredir, explores alternatives

Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Fulcrum Therapeutics Inc (FULC), noting its current financial score of 7.26, which ranks 138 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The report highlights that …

FULC|Fulcrum Therapeutics Inc|Price:3.725|Chg%:-0.005

This article provides a comprehensive stock analysis of Fulcrum Therapeutics Inc (FULC) from TradingKey. It highlights that FULC has relatively weak fundamentals but high growth potential, is fairly valued, and has very high institutional ownership. Analysts generally rate it as a "Hold" with a …

BlackRock discloses 7.2% ownership of Therapeutics Inc (FULC) in updated filing

BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G/A, announcing its beneficial ownership of 7.2% of the common stock of Fulcrum Therapeutics Inc (FULC). This amounts to 4,802,880 shares, with BlackRock holding sole voting power over 4,736,507 shares and sole dispositive power …

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

Kaplan Fox & Kilsheimer LLP has announced an investigation into Fulcrum Therapeutics, Inc. (FULC) for potential securities law violations after the company discontinued its pociredir program for sickle cell disease. This decision followed feedback from the FDA indicating concerns about the benefit-risk profile of …

Fulcrum Therapeutics (FULC) Expected to Release Earnings on Tuesday

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC). This investigation follows the company's announcement on June 1, 2026, to discontinue its pociredir program for sickle cell disease due to heightened FDA concerns regarding the drug's …

Fulcrum Therapeutics Inc (FULC) Institutional Confidence

Fulcrum Therapeutics Inc (FULC) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding proportion stands at 104.53%, a decrease of 26.94% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 2.35M shares, which represents …

Kaplan Fox Launches Securities Probe Into Fulcrum Therapeutics After Pociredir Program Halt Sparks Stock Plunge

Kaplan Fox & Kilsheimer LLP has initiated a securities investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the company's decision on June 1, 2026, to discontinue its pociredir program for sickle cell disease. This announcement led to a significant drop in Fulcrum Therapeutics' stock …

Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Fulcrum Therapeutics Inc (FULC). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also includes current stock information for FULC.

ETFs Investing in Fulcrum Therapeutics, Inc. Stocks

This article lists several ETFs that hold stocks of Fulcrum Therapeutics, Inc. (FULC), a pharmaceuticals company. The list provides details such as market value, weight of FULC in the ETF, issuer, management style, expense ratio, and recent performance for each fund. These ETFs offer …

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm

Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations. This investigation follows Fulcrum's announcement on June 1, 2026, of the discontinuation of its pociredir program for sickle cell disease due to FDA concerns regarding the drug's …